Policy & Regulation
Adimab, Boehringer Ingelheim to Collaborate on Antibody Discovery
12 January 2018 - - Lebanon, New Hampshire-based human monoclonal and bispecific antibodies specialist Adimab, LLC has formed a multi-target partnership with Boehringer Ingelheim (BI), the company said.
Under the terms of the agreement, Adimab will use its proprietary platform to discover and optimize antibodies against targets chosen by BI, who will have the rights to develop and commercialize therapeutic programs resulting from the collaboration.
Under the terms of the agreement, Adimab will use its proprietary yeast-based discovery and optimization platform to identify fully human antibodies against multiple targets selected by BI.
For each target, Adimab will grant BI the right to evaluate antibody panels generated during the collaboration for potential use in therapeutic products.
Adimab will receive an undisclosed upfront payment, research fees, and delivery milestones. In addition, for each target, BI will have an option to exclusively license antibodies generated during the collaboration as therapeutic leads, for which Adimab would receive license fees, clinical milestones and royalties on product sales.
Over the past eight years Adimab has partnered with over 50 pharmaceutical and biotechnology companies.
Adimab's integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs.
The company delivers diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and developability, enabling its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements.


Related Headlines